Literature DB >> 18441595

Regulation of programmed cell death by the p53 pathway.

Kageaki Kuribayashi1, Wafik S El-Deiry.   

Abstract

The p53 pathway is targeted for inactivation in most human cancers either directly or indirectly, highlighting its critical function as a tumor suppressor gene. p53 is normally activated by cellular stress and mediates a growth-suppressive response that involves cell cycle arrest and apoptosis. In the case of cell cycle arrest, p21 appears sufficient to block cell cycle progression out of G1 until repair has occurred or the cellular stress has been resolved. The p53-dependent apoptotic response is more complex and involves transcriptional activation of multiple proapoptotic target genes, tissue, and signal specificity, as well as additional events that are less well understood. In this chapter, we summarize the apoptosis pathway regulated by p53 and include some open questions in this field.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18441595     DOI: 10.1007/978-1-4020-6554-5_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  33 in total

1.  A unique role for ITK in survival of invariant NKT cells associated with the p53-dependent pathway in mice.

Authors:  Qian Qi; Weishan Huang; Yuting Bai; Gabriel Balmus; Robert S Weiss; Avery August
Journal:  J Immunol       Date:  2012-03-07       Impact factor: 5.422

2.  Model study of biological effects of weak static magnetic fields at the organismic and subcellular levels.

Authors:  V E Stefanov; B F Shchegolev; O V Kriyachko; N V Kuzmenko; S V Surma; I M Spivak
Journal:  Dokl Biol Sci       Date:  2015-05-05

3.  Hip2 ubiquitin-conjugating enzyme has a role in UV-induced G1/S arrest and re-entry.

Authors:  Nan Hee Hong; Yeong Jin Tak; Hyangshuk Rhim; Seongman Kang
Journal:  Genes Genomics       Date:  2018-09-27       Impact factor: 1.839

4.  Influence of nonprotective autophagy and the autophagic switch on sensitivity to cisplatin in non-small cell lung cancer cells.

Authors:  Nipa H Patel; Jingwen Xu; Tareq Saleh; Yingliang Wu; Santiago Lima; David A Gewirtz
Journal:  Biochem Pharmacol       Date:  2020-03-03       Impact factor: 5.858

5.  The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo.

Authors:  Kageaki Kuribayashi; Niklas Finnberg; John R Jeffers; Gerard P Zambetti; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

6.  The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions.

Authors:  Zhigang Yuan; Alejandro Villagra; Lirong Peng; Domenico Coppola; Michele Glozak; Eduardo M Sotomayor; Jiandong Chen; William S Lane; Edward Seto
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

7.  Substituted E-3-(3-indolylmethylene)-1,3-dihydroindol-2-ones with antitumor activity. In depth study of the effect on growth of breast cancer cells.

Authors:  Aldo Andreani; Stefania Bellini; Silvia Burnelli; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Natalia Calonghi; Concettina Cappadone; Maddalena Zini; Claudio Stefanelli; Lanfranco Masotti; Robert H Shoemaker
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

8.  Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.

Authors:  M T de Bruijn; D A E Raats; F J H Hoogwater; W J van Houdt; K Cameron; J P Medema; I H M Borel Rinkes; O Kranenburg
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

9.  Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53.

Authors:  Stephen M Sykes; Timothy J Stanek; Amanda Frank; Maureen E Murphy; Steven B McMahon
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

10.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.